Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vir Biotechnology Inc (NQ: VIR )

30.14 +0.23 (+0.77%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 859,718
Open 29.91
Bid (Size) 29.55 (1)
Ask (Size) 31.00 (5)
Prev. Close 29.91
Today's Range 29.35 - 30.95
52wk Range 18.05 - 34.97
Shares Outstanding 133,115,621
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
The 7 Most Undervalued Biotech Stocks to Buy in February 2023
Get your hands on the latest medical innovations at a compelling discount with the most undervalued biotech stocks to buy. 
Via InvestorPlace
7 Healthcare Stocks That Will Be Big Winners in 2023
Healthcare stocks had a strong 2022 which will continue throughout 2023 making these picks ones to consider. 
Via InvestorPlace

Performance

YTD
+20.95%
+20.95%
1 Month
+19.60%
+19.60%
3 Month
+17.46%
+17.46%
6 Month
-0.10%
-0.10%
1 Year
-9.92%
-9.92%

More News

Read More
5 Value Stocks In The Healthcare Sector
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023
Via Benzinga
Analyst Expectations for Vir Biotechnology's Future
Via Benzinga
2 Fast-Growing Healthcare Stocks to Buy and Hold
Via The Motley Fool
Data From Multiple Ongoing Trials Of Vir Biotech's HBV Therapies Show Promising Action
Via Benzinga
Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor
From Vir Biotechnology, Inc.
Via Globe NewsWire
2 Stocks That Could Turn $100 Into $1,000 by 2028
Via The Motley Fool
Vir Biotechnology to Highlight Anticipated 2023 Catalysts and Long-Term Growth Strategy at 41st Annual J.P. Morgan Healthcare Conference
From Vir Biotechnology, Inc.
Via Globe NewsWire
Vir Biotechnology Achieves Target Enrollment for Groundbreaking Phase 2 PENINSULA Trial Evaluating VIR-2482 for Prevention of Seasonal Influenza A
From Vir Biotechnology, Inc.
Via Globe NewsWire
Why Vir Biotechnology Jumped Nearly 19% Today
Via The Motley Fool
BioNTech, Vertex Pharmaceuticals And Other Big Biotechnology Stocks From Benzinga's Most Accurate Analysts
Via Benzinga
European Official Says COVID-19 Booster Uptake Disappointing In The Region
Via Benzinga
After Bill Gates Dumps Billions In Berkshire To Buy Microsoft, His Quiet Biotech Portfolio Has Made A New Trade
Via Benzinga
Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™
From Vir Biotechnology, Inc.
Via Globe NewsWire
Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says
Via Benzinga
FDA Moves Step Closer For Opioid Overdose Medication Access, Says Certain Naloxone Products Can Potentially Be Used In OTC Setting
Via Benzinga
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection
From Vir Biotechnology, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why MediaAlpha Shares Jumped Around 30%; Here Are 112 Biggest Movers From Friday
Via Benzinga
Why Yelp Shares Are Trading Lower By 15%? Here Are 86 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
What 5 Analyst Ratings Have To Say About Vir Biotechnology
Via Benzinga
Vir Obliterates Quarterly Sales Expectations As Covid Drug Delivers Triple-Digit Growth
Via Investor's Business Daily
Block, MasTec, Universal Display And Some Other Big Stocks Moving Higher On Friday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.